Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: Current Clinical Pathology
Editat de Michael J. Murphyen Limba Engleză Hardback – dec 2011
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1538.80 lei 6-8 săpt. | |
Humana Press Inc. – 23 aug 2016 | 1538.80 lei 6-8 săpt. | |
Hardback (1) | 1368.20 lei 6-8 săpt. | |
Humana Press Inc. – dec 2011 | 1368.20 lei 6-8 săpt. |
Din seria Current Clinical Pathology
- 14% Preț: 635.85 lei
- 5% Preț: 1058.59 lei
- 5% Preț: 1385.76 lei
- 5% Preț: 685.18 lei
- 5% Preț: 1055.95 lei
- 5% Preț: 992.85 lei
- 5% Preț: 1056.85 lei
- 5% Preț: 1388.40 lei
- 5% Preț: 1062.83 lei
- 5% Preț: 1378.21 lei
- 5% Preț: 1386.65 lei
- 5% Preț: 1055.07 lei
- 5% Preț: 971.13 lei
- 5% Preț: 1096.39 lei
- 5% Preț: 355.41 lei
- 5% Preț: 663.65 lei
- 5% Preț: 699.75 lei
- 5% Preț: 1101.66 lei
- 5% Preț: 356.82 lei
- 5% Preț: 693.11 lei
- 5% Preț: 791.37 lei
- 5% Preț: 801.40 lei
- 5% Preț: 331.42 lei
- 5% Preț: 632.22 lei
- 5% Preț: 2064.06 lei
Preț: 1368.20 lei
Preț vechi: 1440.21 lei
-5% Nou
Puncte Express: 2052
Preț estimativ în valută:
261.85€ • 276.21$ • 218.84£
261.85€ • 276.21$ • 218.84£
Carte tipărită la comandă
Livrare economică 31 decembrie 24 - 14 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781607614326
ISBN-10: 1607614324
Pagini: 336
Ilustrații: XIV, 322 p.
Dimensiuni: 178 x 254 x 25 mm
Greutate: 0.73 kg
Ediția:2012
Editura: Humana Press Inc.
Colecția Humana
Seria Current Clinical Pathology
Locul publicării:Totowa, NJ, United States
ISBN-10: 1607614324
Pagini: 336
Ilustrații: XIV, 322 p.
Dimensiuni: 178 x 254 x 25 mm
Greutate: 0.73 kg
Ediția:2012
Editura: Humana Press Inc.
Colecția Humana
Seria Current Clinical Pathology
Locul publicării:Totowa, NJ, United States
Public țintă
Professional/practitionerCuprins
Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma.- Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play.- Molecular Pathogenesis of Melanoma: Established and Novel Pathways.- Staging of Melanoma.- Clinical and Histopathological Parameters in Melanoma.- Genetic/Epigenetic Biomarkers: Distinction of Melanoma from Other Melanocytic Neoplasms.- mRNA Biomarkers in Melanoma.- Epigenetic Biomarkers in Melanoma.- microRNA Biomarkers in Melanoma.- MicroRNAs as Biomarkers and Therapeutic Targets in Melanoma.- Mitochondrial DNA Biomarkers in Melanoma.- Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (A) Diagnosis.- Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (B) Prognostication.- Tissue-Based Protein Biomarkers in Melanoma: Mass Spectrometry-Based Strategies.- Serological Biomarkers in Melanoma.- Molecular Markers of Lymph Node Disease in Melanoma.- Melanoma Cell Propagation: Cancer Stem Cell, Clonal Evolution and Interconversion Models of Tumorigenicity.- Surgical Management of Melanoma: Concept of Field Cancerization and Molecular Evaluation of Tissue Margins.- Chemotherapy for Melanoma.- Molecular-Targeted Therapy for Melanoma.- Anti-Angiogenesis Therapy for Melanoma.- Immunological Biomarkers and Immunotherapy for Melanoma.- Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview.
Recenzii
From the reviews:
“This is a comprehensive overview of biomarkers as they relate to pathogenesis and clinical utility in the diagnosis, staging, and treatment of melanoma. … The audience is practitioners specializing in melanoma, including dermatologists, surgeons, and oncologists, as well as researchers in the field. … book broadly explores the role of molecular diagnostic techniques and specific biomarkers which may serve to facilitate more accurate diagnoses and identify early-stage melanoma patients with high risk for metastasis. … I highly recommend this book for melanoma clinicians and researchers.” (Susan M. Swetter, Doody’s Book Reviews, July, 2012)
“This is a comprehensive overview of biomarkers as they relate to pathogenesis and clinical utility in the diagnosis, staging, and treatment of melanoma. … The audience is practitioners specializing in melanoma, including dermatologists, surgeons, and oncologists, as well as researchers in the field. … book broadly explores the role of molecular diagnostic techniques and specific biomarkers which may serve to facilitate more accurate diagnoses and identify early-stage melanoma patients with high risk for metastasis. … I highly recommend this book for melanoma clinicians and researchers.” (Susan M. Swetter, Doody’s Book Reviews, July, 2012)
Textul de pe ultima copertă
This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.
Caracteristici
Reviews major advances in molecular methods, using an evidence-based perspective Explores powerful tools for determining treatment decisions An essential resource for oncologists, dermatologists, pathologists, and melanoma researchers Includes supplementary material: sn.pub/extras